Back
PTC Therapeutics, Inc. (PTCT)
BiotechnologyPTCT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$64.70
+3.45%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$7.73
ROE
Gross margin
38.3%
Debt/Equity
Revenue growth
-76.8%
P/B ratio
Beta
Forward P/E
PTC Therapeutics, Inc. — company intelligence
Earnings surprises
Q2 2026$0.92 vs $0.43 est+116.4%
Q1 2026$-0.03 vs $-0.48 est+93.7%
Q4 2025$-1.67 vs $0.04 est-4460.3%
Q3 2025$0.20 vs $-1.40 est+114.3%
Analyst consensus · 21 analysts
17 Buy3 Hold1 Sell
Updated Oct 9, 2026
Insider activity · 90 days
4 buys20 sellsnet -95,386 shares
SCHMERTZLER MICHAELSell 9,624 · Sep 17, 2026
SCHMERTZLER MICHAELSell 376 · Sep 17, 2026
SCHMERTZLER MICHAELSell 2,994 · Sep 16, 2026
Recent SEC filings
8-K — Material event reportSep 21, 2026
4 — Insider transaction reportSep 18, 2026
4 — Insider transaction reportSep 11, 2026
Latest news
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75 — Benzinga · 2d ago
Is PTC Stock Increasing Your Market Risk? — Yahoo · 4d ago
Which Gives You More Of Hard-To-Replace Software, PTC Or Fair Isaac? — Yahoo · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.